Litcius/Paper detail

Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial

Michiel S. van der Heijden, Yohann Loriot, Ignacio Durán, Alain Ravaud, Margitta Retz, Nicholas J. Vogelzang, B. Nelson, Jingjing Wang, Xiaodong Shen, Thomas Powles

2021European Urology121 citationsDOI

Topics & Concepts

AtezolizumabMedicineMetastatic Urothelial CarcinomaOncologyChemotherapyInternal medicineDiscontinuationDocetaxelAdverse effectImmunotherapyUrologyCancerBladder cancerPembrolizumabUrothelial carcinomaBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and Biomarkers
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial | Litcius